Complement Membrane Attack Complex
AN2 Therapeutics Cuts 50% of Staff and Discontinues Epetraborole Program for MAC Lung Disease
AN2 Therapeutics, epetraborole, MAC lung disease, Phase II/III trial, workforce reduction, restructuring, melioidosis, Chagas disease